Related Experiment Video
Updated: Sep 7, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
Dysregulation of splicing variants and spliceosome components in breast cancer
Manuel D Gahete1,2,3,4, Natalia Herman-Sanchez1,2,3,4, Antonio C Fuentes-Fayos1,2,3,4
1Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain.
Abstract:
The dysregulation of the splicing process has emerged as a novel hallmark of metabolic and tumor pathologies. In breast cancer (BCa), which represents the most diagnosed cancer type among women worldwide, the generation and/or dysregulation of several oncogenic splicing variants have been described. This is the case of the splicing variants of HER2, ER, BRCA1, or the recently identified by our group, In1-ghrelin and SST5TMD4, which exhibit oncogenic roles, increasing the malignancy, poor prognosis, and resistance to treatment of BCa. This altered expression of oncogenic splicing variants has been closely linked with the dysregulation of the elements belonging to the macromolecular machinery that controls the splicing process (spliceosome components and the associated splicing factors). In this review, we compile the current knowledge demonstrating the altered expression of splicing variants and spliceosomal components in BCa, showing the existence of a growing body of evidence supporting the close implication of the alteration in the splicing process in mammary tumorigenesis.
Insights
Altered gene splicing and spliceosome machinery are key in breast cancer (BCa) development. This review highlights how splicing dysregulation drives BCa malignancy and poor prognosis.
Area of Science:
- Molecular Biology
- Oncology
- Cancer Research
Background:
- Splicing dysregulation is a hallmark of metabolic and tumor pathologies.
- Breast cancer (BCa) exhibits dysregulation of oncogenic splicing variants like HER2, ER, BRCA1, In1-ghrelin, and SST5TMD4.
- These variants increase BCa malignancy, poor prognosis, and treatment resistance.
Purpose of the Study:
- To review current knowledge on altered splicing variants and spliceosome components in BCa.
- To demonstrate the link between splicing alterations and mammary tumorigenesis.
Main Methods:
- Literature review of studies on splicing variants and spliceosome components in BCa.
- Compilation of evidence linking splicing alterations to breast cancer development.
Main Results:
- Altered expression of specific oncogenic splicing variants (In1-ghrelin, SST5TMD4) is identified in BCa.
- Dysregulation of spliceosome components and splicing factors is closely linked to altered splicing variants.
- Growing evidence supports the role of splicing process alterations in mammary tumorigenesis.
Conclusions:
- Splicing dysregulation is a significant factor in breast cancer.
- Targeting splicing machinery may offer novel therapeutic strategies for BCa.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
What is Gene Expression?
Pre-mRNA Processing: RNA Splicing
MicroRNAs

